Abstract:Background Hepatocellular carcinoma (HCC) presents one of the major health threats in China today. A better understanding of the molecular genetics underlying malignant transformation of hepatocytes is critical to success in the battle against this disease. The methylation state of C5 of the cytosine in the CpG di-nucleotide that is enriched within or near the promoter region of over 50 % of the polymerase II genes has a drastic effect on transcription of these genes. Changes in the methylation profile of the promoters represent an alternative to genetic lesions as causative factors for the tumor-specific aberrant expression of the genes. Methods We have used the methylation specific PCR method in conjunction with DNA sequencing to assess the methylation state of the promoter CpG islands of twenty genes. Aberrant expression of these genes have been attributed to the abnormal methylation profile of the corresponding promoter CpG islands in human tumors. Results While the following sixteen genes remained the unmethylated in all tumor and normal tissues: CDH1, APAF1, hMLH1, BRCA1, hTERC, VHL, RARβ, TIMP3, DAPK1, SURVIVIN, p14 ARF , RB1, p15 INK4b , APC, RASSF1c and PTEN, varying degrees of tumor specific hypermethylation were associated with the p16 INK4a , RASSF1a, CASP8 and CDH13 genes. For instance, the p16 INK4a was highly methylated in HCC (17/29, 58.6%) and less significantly methylated in non-cancerous tissue (4/29. 13.79%). The RASSF1a was fully methylated in all tumor tissues (29/29, 100%), and less frequently methylated in corresponding non-cancerous tissue (24/29, 82.75%). Conclusions Furthermore, co-existence of methylated with unmethylated DNA in some cases suggested that both genetic and epigenetic (CpG methylation) mechanisms may act in concert to inactivate the p16 INK4a and RASSF1a in HCC. Finally, we found a significant association of cirrhosis with hypermethylation of the p16 INK4a and hypomethylation of the CDH13 genes. For the first time, the survey was carried out on such an extent that it would not only provide new insights into the molecular mechanisms underscoring the aberrant expression of the genes in this study in HCC, but also offer essential information required for a good methylation-based diagnosis of HCC.

Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.

Association of Low P16ink4a and P15ink4b Mrnas Expression with Their Cpg Islands Methylation with Human Hepatocellular Carcinogenesis

BCL6B Hypermethylation Predicts Metastasis and Poor Prognosis in Early-Stage Hepatocellular Carcinoma after Thermal Ablation

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Bmp4 Enhances Hepatocellular Carcinoma Proliferation by Promoting Cell Cycle Progression Via Id2/Cdkn1b Signaling

Aberrant Methylation Status of SPG20 Promoter in Hepatocellular Carcinoma: A Potential Tumor Metastasis Biomarker.

Promoter Hypomethylation is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma.

BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial–mesenchymal transition via upregulating ID2

Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells.

Hypermethylation of ACP1 , BMP4 , and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance

Aberrant Enhancer Hypomethylation Contributes to Hepatic Carcinogenesis Through Global Transcriptional Reprogramming

Integrative Analysis of Epigenome and Transcriptome Data Reveals Aberrantly Methylated Promoters and Enhancers in Hepatocellular Carcinoma

MP23-19 EZH2 CONTRIBUTES TO PROLIFERATION AND METASTASIS IN RENAL CELL CARCINOMA CELLS

DNA Hypermethylation Modification Promotes the Development of Hepatocellular Carcinoma by Depressing the Tumor Suppressor Gene ZNF334

Integrated Analyses of DNA Methylation and Hydroxymethylation Reveal Tumor Suppressive Roles of ECM1 , ATF5 , and EOMES in Human Hepatocellular Carcinoma

Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis

Reduced BMP6 Expression by DNA Methylation Contributes to EMT and Drug Resistance in Breast Cancer Cells.

Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma